Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingLLY
Biotech & Genomic Medicine▼
Novo's oral version of Wegovy accepted for review in China
Danish pharmaceutical giant Novo Nordisk said on the 27th that Chinese drug regulators have accepted its application for the oral version of its obesity treatment Wegovy. The company is trying to catch up with rival Eli Lilly in the world's second-largest pharmaceutical market. Eli Lilly, which is ahead in China, announced in March that it had submitted an application for marketing approval for Orforglipron to Chinese regulators by the end of 2025, and company executives have said it could be launched in China as early as this year. Novo was asked for comment on how long approval for Wegovy might take, but as it was outside business hours, no response has been received so far.
Veeva Systems reported a record second quarter for fiscal 2027, with total revenue of $928 million and non-GAAP operating income of $416 million, both exceeding guidance. The company achieved its best-ever CRM quarter, with two TOP20 biopharma customers, Lilly and Biogen, selecting Vault CRM, bringing the total to 12 of TOP20. Veeva Falcon, its agentic AI product, is generating high customer interest, with early adopters showing promising results and faster implementation. Commercial subscription revenue grew 13% year-over-year, with broad-based strength across CRM, content, data, and Crossix. The company also highlighted progress with its Aspen product, priced at $50 per user per month, and its partnership with IQVIA, which CEO Peter Gassner called one of the best things to happen to Veeva in the past 12 months.
Eli Lilly Wins FDA Approval for Alzheimer's Blood Test
Eli Lilly has secured FDA approval for a new Alzheimer's blood test developed with Roche, which can help identify signs of the disease in adults 55 and older experiencing cognitive decline. The test, called Elecsys pTau217, measures a biomarker associated with Alzheimer's-related brain changes and is designed to help physicians determine whether patients are likely or unlikely to have those changes, though it is not intended as a standalone diagnosis. The approval broadens Lilly's exposure beyond its obesity and diabetes franchises and could make Alzheimer's testing more accessible by reducing reliance on costly brain scans and invasive spinal-fluid testing. More than 4,500 Roche laboratory analyzers already installed across the U.S. can run the test, potentially allowing hospitals and clinics to adopt it without major new infrastructure investment. The FDA decision follows European approval in May, and Lilly shares were down about 2% on August 26 amid a broader market decline despite the approval.
US Administration to Announce Drug Price Agreement with Mid-Sized Biotech Firms on 31st
The Trump administration is expected to announce a new agreement on drug prices with mid-sized biopharmaceutical companies on the 31st. Bloomberg reported on the 26th, citing sources. According to the report, the companies have agreed to lower prices for outpatient prescription drugs under Medicaid, the public health insurance program for low-income individuals, with the aim of bringing the prices paid by states in line with those charged overseas. It is not clear which pharmaceutical companies will be part of the agreement. Reuters has not yet confirmed the report. President Trump has previously sent letters to the CEOs of 17 major pharmaceutical companies, including Pfizer, Eli Lilly, and Amgen, urging them to reduce U.S. prescription drug prices to levels comparable to those overseas.
Lilly Study Shows Zepbound Cuts Costs, Excludes Drug Price
Eli Lilly, the obesity-drug and pharmaceutical heavyweight, traded at $1,215.89 Wednesday after releasing a real-world study of 15,843 adults over 55 that linked sustained use of its weight-loss drug Zepbound to fewer hospital stays, fewer emergency-room visits, and lower medical bills. After 12 months, two analytical methods estimated that patients saved $319 to $607 per month, 25% to 38% less than comparable untreated adults. However, Zepbound's price was excluded because the claims data did not capture its net cost, meaning the study measured potential savings before the cost of the drug itself. The projected savings equal roughly 1.6 to 3.1 times the GLP-1 Bridge program's $195 monthly treatment cost, giving Lilly fresh ammunition in its campaign for broader Medicare coverage. Yet this was a retrospective study, so it shows a relationship rather than proving Zepbound caused every dollar saved. At $1,215.89, the shares sit 20.01% below the GF Value estimate of about $1,520, suggesting Wall Street still wants harder proof before closing the gap.
Zepbound linked to lower healthcare costs in older adults with obesity
Eli Lilly and Company announced results from a real-world study showing that sustained use of Zepbound (tirzepatide) in adults over 55 with overweight or obesity lowers healthcare costs over time, driven partly by fewer hospital admissions and emergency department visits. The first-of-its-kind study, published in Diabetes, Obesity and Metabolism, found that at six months, costs were up to 15% lower (up to $181 per patient per month), and by 12 months, the difference widened to up to $607 per patient per month, reflecting on average 38% lower costs than untreated adults. These savings nearly covered the Medicare GLP-1 Bridge program's monthly treatment cost of $195 per patient per month starting at six months, and exceeded the cost of Zepbound treatment by 12 months. The analysis included 15,843 adults with a mean age of 64.5 years, and used two methods that both showed consistent results. Ilya Yuffa, president of Lilly USA, said the evidence highlights the impact of treating obesity on older patients and the healthcare system, and should help shape coverage decisions as Medicare and other payers expand access.
BioArctic Q2 2026: Eli Lilly Deal and FDA Approval Boost
BioArctic reported its interim results for the second quarter of 2026, highlighting new approvals for Leqembi and strategic partnerships. The company entered into a research collaboration with Eli Lilly, receiving an upfront payment of USD 30 million, with the agreement worth up to USD 800 million plus royalties. Additionally, the FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation treatment in early Alzheimer's disease, leading to a US launch in August. BioArctic also entered into a research collaboration in oncology with the Swedish biotech company Mesenkia Therapeutics to explore a novel antibody-based treatment for glioblastoma. Net revenues for the quarter amounted to SEK 247.5 million, with royalty income from Leqembi at SEK 179.4 million, while operating profit was SEK -6.5 million and earnings per share before dilution were SEK -0.13.
14% of US Employers to End Obesity Drug Coverage by 2027
A survey by the industry group Business Group on Health found that about 14% of US employers plan to end insurance coverage for obesity drugs known as GLP-1 receptor agonists by 2027. The reason is rising healthcare costs, and if companies do not implement cost-containment measures, healthcare costs in 2027 are projected to increase by 9.2% year-over-year. About two-thirds of responding companies confirmed expanded use of GLP-1 drugs. Notable products include Novo Nordisk's Wegovy and Eli Lilly's Zepbound, with list prices of $1,349.02 and $499 per month, respectively. Ellen Kelsay of the group said, "Companies are finding it difficult to budget and forecast costs." Drug costs account for 25% of total corporate healthcare spending and are expected to rise 12% year-over-year by 2027. The percentage of companies covering GLP-1 drugs for obesity fell from 72% in 2025 to 60% in 2026.
Lilly Gains as Foundayo Crosses the Atlantic Without a Needle
Eli Lilly shares rose about 1.3% to $1,262.60 Tuesday morning as its once-daily weight-loss pill Foundayo launched in Britain's private-prescription market, marking the company's first European rollout for the drug. The launch comes before Lilly secures broader access through England's National Health Service. Patients taking the highest dose in Lilly's pivotal U.S. obesity trial lost an average of 27 pounds. Lilly's second-quarter revenue surged 48% to $23 billion, prompting management to raise its full-year revenue forecast to between $85 billion and $87 billion. The stock trades 16.89% below its $1,520 GF Value estimate, and the company now faces competition from Novo Nordisk's oral Wegovy.
Eli Lilly Widens Lead Over Novo Nordisk in Weight-Loss Drug Race
Eli Lilly and Novo Nordisk reported sharply contrasting second-quarter 2026 results, with Lilly posting 48% revenue growth and raising full-year guidance while Novo cut nearly 12,000 employees and took a DKK 6.3 billion impairment. Lilly's Mounjaro and Zepbound combined for $14.9 billion in quarterly sales, with China up 93% and rest of world up 136% at constant currency, and the company now controls roughly 6 out of 10 U.S. obesity prescriptions. Novo's adjusted sales rose 7% at constant exchange rates to 78.5 billion Danish kroner, but adjusted gross margin fell to 78.2% from 82.7% a year earlier, and its oral Wegovy pill reached over 5 million total prescriptions with about 90% of the oral obesity market. Lilly's triple-acting GLP-1 retatrutide hit primary endpoints across three Phase 3 trials with weight loss approaching bariatric surgery levels at the highest doses, and the company targets a U.S. BLA submission in Q1 2027, while full-year revenue guidance moved to $85 to $87 billion.
Eli Lilly Slips as Its $1.1 Trillion Valuation Cools
Eli Lilly shares slipped to $1,245.40 Monday afternoon after charging toward their 52-week high, as investors took profits on the pharmaceutical heavyweight behind Mounjaro and Zepbound. Second-quarter revenue exploded 48% to $23 billion, with Mounjaro sales nearly doubling to $9.94 billion and Zepbound jumping 46% to $4.93 billion. Lilly raised its full-year revenue forecast to between $85 billion and $87 billion. The stock trades 17.97% below its GF Value estimate of roughly $1,520, signaling potential upside, though Mounjaro and Zepbound now generate nearly two-thirds of companywide sales.
Eli Lilly Sues Six Companies Over Unapproved Retatrutide Sales
Eli Lilly and Company filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide, an experimental obesity drug still in Phase 3 trials and not yet approved by regulators anywhere. The lawsuits target compounding pharmacies, medical spas, and online sellers, and Lilly said it has referred more than 200 individuals and entities to the FDA, the Justice Department, state attorneys general, and law enforcement. Lilly Chief Medical Officer Dr. David Hyman said what's being sold on the black market "is entirely unverified, unapproved and not worth the risk." US Customs and Border Protection told Reuters it intercepted more than 690 shipments of illicit GLP-1 drugs in fiscal 2025, and that pace has since accelerated sharply, with more than 1,400 seizures in July 2026 alone. In trials, retatrutide helped overweight or obese patients with type 2 diabetes lose nearly 13% of their body weight after 80 weeks, and Lilly plans to submit it for US approval as a biologic in the first quarter of 2027.
Novo Nordisk CEO Says Obesity Drug Market Will Fragment Beyond Lilly Rivalry
Novo Nordisk CEO Mike Doustdar told Reuters on August 13, 2026 that investors are underestimating how much the obesity drug market will fragment as new treatments arrive, pushing back on the idea that Novo and Eli Lilly are locked in a zero-sum battle. Doustdar said the market will not be "Coke versus Pepsi. It will be Coke and Pepsi and Fanta and Dr Pepper and Red Bull," arguing patients will sort themselves across many differentiated GLP-1 options rather than one winner taking the whole category. He noted Novo's oral Wegovy pill already holds 90% share of the oral GLP-1 market, partly because its data shows better weight loss than Lilly's Foundayo pill, and compared his ambitions for the obesity portfolio to Novo's insulin business, where it sells half the world's insulin across 12 different brands. Novo's next-generation obesity drug CagriSema helped patients lose an average of 23% of their body weight in trials, trailing the more than 25% seen with Lilly's Zepbound, and Doustdar acknowledged the drug "has been written off pretty much by all investors." The obesity market Novo and Lilly are fighting over is expected to be worth more than $100 billion a year by 2030, according to analyst estimates, which means even small share shifts carry enormous financial stakes. Lilly's market capitalization has continued climbing past $1 trillion, a sign investors currently favor Lilly's execution over Novo's broader segmentation argument, and Lilly was held by 132 hedge funds as of Q1 2026, down from 137 the prior quarter, while Novo held steady at 55 holders.
Eli Lilly's $87 Billion Guidance Puts $100 Billion Revenue Milestone Within Reach
Eli Lilly has guided fiscal 2026 revenue between $85 billion and $87 billion, putting the $100 billion revenue milestone within reach. The company's Q2 2026 revenue of $22.97 billion grew 47.67% year over year and beat consensus by 11.06%, while EPS of $8.38 beat by 27.27%. Mounjaro delivered $9.94 billion, up 91%, and Zepbound added $4.93 billion. 24/7 Wall St. maintains a buy rating and a $1,480.01 price target, implying 17.89% upside, with a bull-case target of $1,704.19. Retatrutide's Q1 2027 BLA and orforglipron's global rollout are key catalysts.
Eli Lilly's Doubled Operating Margin Rests on Volume, Not Price
Eli Lilly's operating margin nearly doubled to 49.7% in the June 2026 quarter, driven by volume growth rather than price increases. Total revenue rose 48% year over year while marketing, selling and administrative costs grew only 25%, with Mounjaro and Zepbound contributing $14.9 billion of revenue and $6.3 billion of the growth. Management raised full-year 2026 revenue guidance to $85 billion to $87 billion and lifted its non-GAAP performance margin guide to 49% to 50.5%, though U.S. price fell 3%, or 9% excluding rebate and discount adjustments. The Medicare GLP-1 Bridge program expanded obesity drug coverage to 35% more people, and management expects further price declines once broader CVS access begins in Q4 2026, betting that volume growth will more than offset the erosion.
Rznomics Inc., a South Korean biopharmaceutical company specializing in RNA-based gene therapies, announced it is joining Lilly Gateway Labs in San Diego, California. The move is intended to accelerate candidate discovery and development across its target gene database bank of over 200 disease targets, while also supporting long-term efforts to establish global clinical infrastructure for its lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the U.S. Lilly Gateway Labs is an innovation hub that provides wet lab facilities and opportunities to engage with Lilly scientists and executives, and is part of Lilly Catalyze360 alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab. Rznomics CEO Seong-Wook Lee called the entry a meaningful milestone for the company's proprietary RNA platform, and said the company intends to advance development and commercialization of its RNA therapeutics through active collaboration with the global biotech ecosystem. Rznomics signed a research collaboration and license agreement with Eli Lilly and Company in May 2025 for development of a novel RNA editing therapeutic, and listed on the KOSDAQ market in December 2025.
Eli Lilly Commits to Veeva Vault CRM Globally as Leadership Shifts
Veeva Systems has secured Eli Lilly and Company's commitment to deploy Veeva Vault CRM globally, while announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. The Eli Lilly win reinforces the thesis that top 20 pharma are increasingly willing to consolidate critical commercial workflows on Veeva's platform, tying directly into consensus expectations for continued subscription and services growth. Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, with the company's narrative projecting $4.7 billion revenue and $1.4 billion earnings by 2029, requiring 12.7% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today. Some analysts expect Veeva to reach about US$4.5 billion in revenue and US$1.3 billion in earnings by 2029, while the most cautious voices see AI agents, especially in Safety and clinical workflows, as a swing factor that could reshape those forecasts. The leadership change in Sales and Services does not appear to materially shift the biggest short term risk around customer concentration and contract renewals.
Eli Lilly Gains UK Approval for Foundayo Oral GLP-1 Pill
Eli Lilly secured UK approval for Foundayo, its once-daily oral GLP-1 pill for weight management and type 2 diabetes, while reporting strong revenue growth driven by Mounjaro and Zepbound and raising full-year guidance. The company also advanced its next-generation GLP-1 pipeline and is pursuing legal action against unauthorized retatrutide sellers. Analysts project Lilly's revenue could reach $118.0 billion and earnings $48.7 billion by 2029, requiring 14.0% yearly revenue growth. The most optimistic forecasts model revenues of about $124.5 billion and earnings near $50.0 billion, though payer resistance to obesity drug reimbursement remains a key risk.
Bristol-Myers Squibb to Spend $2.3 Billion on Houston Plant
Bristol-Myers Squibb announced on August 10 that it will invest about $2.3 billion in a new manufacturing plant in Houston, part of a larger $40 billion U.S. investment pledge. The roughly 600,000-square-foot campus will produce small-molecule medicines, biologics, and antibody-drug conjugates, and is expected to create close to 500 skilled jobs and about 2,000 construction jobs between 2027 and 2030. Texas is providing $4.89 million in state funding for the project. The move comes as drugmakers including Eli Lilly, Johnson & Johnson, and Pfizer expand U.S. manufacturing amid tariff pressure from the Trump administration. Separately, British regulators cleared Eli Lilly's weight-loss pill Foundayo for weight management and type 2 diabetes, making the UK the first country in Europe to approve the drug.
PWIN and PWINRMF funds benefit from healthcare stock surge
The Phillip World Innovation Fund, or PWIN, and the Phillip World Innovation Retirement Mutual Fund, or PWINRMF, have received a positive boost from the global rise in healthcare stocks, one of the three core investment themes the funds emphasize, alongside information technology, semiconductors, AI and data centers, and clean energy infrastructure. The S&P 500 Healthcare Index has risen 10.8% since the outbreak of conflict in the Middle East, calculated from the closing price on March 2, 2026, compared with the closing price on August 19, 2026, according to Bloomberg data. A specific positive factor came from late-stage trial results in patients with melanoma skin cancer, indicating that the use of Moderna's mRNA vaccine in combination with Merck's Keytruda produced positive outcomes. This sent Moderna's share price soaring by as much as 176% and lifted Merck's shares by 12% on August 19 alone. Other healthcare stocks such as Eli Lilly, Novartis, and Pfizer also saw significant gains.
Corcept Leads Branded Pharma Q2 With 21.6% Revenue Beat
Corcept Therapeutics reported second-quarter revenues of $256.1 million, up 31.7% year on year and beating analysts' expectations by 21.6%, making it the standout performer among eight branded pharmaceutical stocks tracked. The company also beat EPS estimates and raised full-year revenue guidance above expectations, with its stock up 28.1% since reporting to trade at $119.05. Bristol-Myers Squibb posted revenues of $12.97 billion, up 5.7% and 12.9% above estimates, while Eli Lilly delivered the fastest revenue growth at 47.7% to $22.97 billion, beating by 11.4%. Zoetis was the weakest, with flat revenues of $2.47 billion missing estimates by 1.5% and lowering full-year guidance. Supernus Pharmaceuticals reported $211.3 million in revenue, up 27.7% and 2.8% above estimates.
Novo Nordisk Launches Once-Weekly Insulin Awiqli in US
Novo Nordisk has launched Awiqli, the first once-weekly basal insulin for adults with type 2 diabetes, in the United States following FDA approval in March and nationwide availability in August. The therapy reduces basal insulin injections from seven to one per week, offering a more convenient alternative to daily dosing. The launch comes as Novo Nordisk seeks to diversify its diabetes franchise amid slower growth and pricing pressure on its core GLP-1 products Ozempic and Wegovy, and intensifying competition from Eli Lilly. Awiqli is already approved in the EU and 13 additional countries, and its U.S. commercial success will depend on physician adoption, patient uptake, and reimbursement coverage. While the new insulin may provide incremental revenue support, its impact is expected to remain modest relative to Novo Nordisk's much larger GLP-1 franchise.
Amplitude Therapeutics and Lilly Partner on Trans-Amplifying RNA Vaccines
Amplitude Therapeutics and Eli Lilly and Company have entered a strategic research collaboration and licensing agreement to develop trans-amplifying RNA vaccine candidates for infectious diseases. The partnership will initially focus on undisclosed infectious disease vaccine programs with high unmet need, with Lilly retaining the option to add up to two additional targets. Under the agreement, Lilly receives exclusive, target-specific rights to develop and commercialize licensed products, while Amplitude leads taRNA optimization and selected preclinical research. Amplitude's taRNA approach separates the replicase and antigen-encoding RNA components, potentially enabling enhanced potency, lower doses, and improved manufacturability compared to other RNA modalities.
Aktis Oncology, a clinical-stage radiopharmaceutical company, is seen as a potential acquisition target for Novartis, Eli Lilly, and Bristol Myers Squibb due to its alpha-emitting cancer platform and upcoming trial data. Aktis retains full worldwide rights to its miniprotein radioconjugate platform, with $517.3 million in cash and preliminary data from its lead candidate AKY-1189 expected in the first quarter of 2027. Novartis, whose Pluvicto grew 43% in Q2 2026, and Eli Lilly, already a $60 million upfront partner, rank as the top two strategic acquirers. Analysts target $34.42 for AKTS while the 24/7 Wall St. base case reaches $42.16, but a failed readout would erase the takeout premium entirely.
Eli Lilly Stock Jumps on Alzheimer's Drug Deal and Ion Channel Collaboration
Eli Lilly shares rose 3.6% to close at $1,227 after the company announced two deals, acquiring rights to a preclinical Alzheimer's drug and entering a collaboration for an ion channel program. The company acquired global rights to AlzeCure Pharma's Alzheimer's drug candidate ACD680 for an upfront payment of $10 million, with the agreement potentially exceeding $1 billion in total value through future development and commercial milestone payments plus mid-single-digit royalties on sales. In a separate agreement, Eli Lilly entered a global collaboration with OmniAb for a new ion channel program, under which OmniAb will receive an upfront payment and is eligible for up to $370 million in milestone payments along with tiered royalties on global net sales. The deals are expected to help Lilly reload its early-stage pipeline while protecting near-term margins and building a fortified multi-mechanism moat around its Alzheimer's franchise.
Eli Lilly Adds Neuroscience and Lung Cancer Research Deals
Eli Lilly announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer. The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline. The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients. These deals expand Eli Lilly's external R&D partnerships across neuroscience and oncology, adding depth to its early and mid stage pipeline.
AlzeCure receives $10 million upfront payment from Lilly
AlzeCure Pharma has received the full USD 10 million upfront payment from Eli Lilly, completing the initial transaction under their collaboration and licensing agreement for the Alzheimer's project Alzstatin. The payment, made pursuant to the agreement signed on June 9, 2026, does not dilute AlzeCure's shareholders. Beyond the upfront payment, the deal includes development and commercial milestone payments plus mid-single-digit royalties on future sales, with a total value excluding royalties that may exceed USD 1 billion. Lilly now holds global rights to Alzstatin and will lead further clinical development and commercialization of the drug candidate ACD680. The transaction closed after customary conditions, including Swedish foreign direct investment screening approval.
OmniAb Inc. shares soared almost 18% in premarket trade after the company raised its cash forecast for 2026 on the back of recent license and business-development agreements. The business now intends to complete the year with $49 million to $53 million in cash and cash equivalents, compared with a prior estimate of $37 million to $41 million. The upgrade comes on the back of recent licensing activities in technology including a contract with Eli Lilly in relation to the company's ion-channel program. Seeking Alpha has previously claimed that the Lilly license deal might be worth $370 million. For a smaller biotech outfit, the capital injection is crucial as it buys management some breathing room on funding operations without needing to tap the equity markets right away.
Eli Lilly Stock Rises 5.8% After Strong Q2 Results
Eli Lilly shares climbed 5.8% after the company reported second-quarter results that beat expectations, with revenue up 48% year over year to $22.97 billion and adjusted EPS up 33% to $8.38. Mounjaro and Zepbound remained the primary growth drivers, and the company raised its sales outlook for the second time this year. Newer medicines across immunology, oncology, and neuroscience also contributed, while the newly launched oral GLP-1 pill Foundayo generated $98 million in its first full quarter. Lilly plans to submit its next-generation candidate retatrutide to the FDA in the first quarter of 2027, and the company has announced more than $20 billion in biotech deals this year. Despite premium valuation and pricing pressures, Zacks maintains a Hold rating on the stock.
Eli Lilly's Foundayo Wins First European Approval in UK
Eli Lilly's weight-loss pill Foundayo won UK approval on August 10, becoming the first European country to clear the drug for both weight management and type 2 diabetes. It is only the second GLP-1 pill approved in Europe, arriving two months after Novo Nordisk's Wegovy pill got its own UK approval in June. Foundayo can be taken at any time of day without food or water restrictions, unlike the Wegovy pill, which must be taken on an empty stomach with a 30-minute wait before eating. Lilly said the drug will launch in the UK later this month through private prescription, priced below Mounjaro's roughly £330 monthly list price. Foundayo already brought in $98 million in US sales last quarter, and Lilly's overall 2026 revenue guidance now sits at $85 billion to $87 billion, up from its earlier forecast, due to strong demand for its weight-loss and diabetes drugs. The Wegovy pill has already topped 5 million prescriptions since its January launch, and roughly 300,000 UK patients started taking it within its first three weeks there, according to CEO Mike Doustdar. Novo Nordisk's second-quarter sales rose 3% in constant currency to 78.49 billion kroner, with adjusted sales up 7%, but Wegovy pill sales of 3.22 billion kroner missed the 3.33 billion kroner analysts expected. Novo has also sued Eli Lilly over allegedly deceptive advertising, a sign of how heated this rivalry has become.
Leal Therapeutics raises $30 million and starts schizophrenia trial
Leal Therapeutics announced a $30 million extension of its Series A financing and the initiation of a Phase 1b/2a clinical trial of LTX-001 in adults with schizophrenia. The financing includes new investor Eli Lilly and Company alongside existing backers OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors' Dementia Discovery Fund, Chugai Venture Fund, Alexandria Venture Investments, and PhiFund. Proceeds will advance LTX-001 through an initial readout from the schizophrenia trial, with data expected by year-end, and progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 trial in amyotrophic lateral sclerosis. LTX-001 is a first-in-class brain-penetrant oral GLS1 inhibitor that has completed Phase 1 single and multiple ascending dose studies with favorable safety and target engagement, while LTX-002 is an intrathecally delivered antisense oligonucleotide targeting SPTLC1.
Weight-loss pills approved in UK could shift consumer demand
More than a third of Britons would consider using new weight-loss pills over injections, according to research from RSM UK, signaling potential pressure on consumer-facing firms to adapt to changing demand. The survey found 34% of people would consider weight-loss medication in tablet form, rising to 43% for millennials and 42% for Gen Z, and 58% among those earning over £80,000 annually. Nearly a quarter of respondents said they had used or were using weight-loss injections, with many reporting smaller portion sizes, less snacking, and less alcohol consumption. Jacqui Baker, head of consumer markets at RSM UK, said GLP-1s could become a catalyst for a broader shift in consumer behaviour, with some categories facing pressure while others, like vitamins and supplements, could benefit. Eli Lilly's daily pill Foundayo was authorised last week by the Medicines and Healthcare products Regulatory Agency, following approval of a pill version of Novo Nordisk's Wegovy in June.
Vinod Khosla Says AI Creates Hyperabundance of New Drugs but Testing Lags
Venture capitalist Vinod Khosla said artificial intelligence is rapidly expanding drug discovery, but traditional testing methods have failed to keep pace with the technology's progress. In a post on X, Khosla said AI has produced what he described as a 21st-century hyperabundance of potential new drugs and biological hypotheses, while drug testing still relies heavily on conventional animal studies. He argued that the industry needs a more human-relevant approach to evaluating potential treatments, pointing to Vivodyne, a biotechnology company developing technology to test drugs using living human tissues at scale. Khosla also said he was excited to continue working with Vivodyne as the company develops its Virtual Human data center, which he said could eventually help researchers predict how patients will respond to treatments. The article also noted that Anthropic launched Claude Science, an AI workbench for scientific research, Takeda reported its AI-developed psoriasis drug zasocitinib significantly outperformed Bristol-Myers Squibb's Sotyktu in a Phase 3 trial, and Nvidia and Eli Lilly announced a $1 billion AI co-innovation lab.
Eli Lilly Commits to Deploy Veeva Vault CRM Globally
Eli Lilly and Company has committed to deploying Veeva Systems' Vault CRM globally, Veeva announced on August 11. Vault CRM serves as the core infrastructure for Veeva's AI-driven commercial framework, designed to modernize field engagement and speed medicine delivery. The partnership highlights how technology and drug development are becoming deeply intertwined, with Veeva as the tech engine and Eli Lilly as the pharmaceutical titan. In its fiscal 2027 first quarter, Veeva reported total revenue of $882.9 million, up 16% year-over-year, while Eli Lilly's second quarter 2026 revenue surged 48% to $22.97 billion, driven by GLP-1 therapies Mounjaro and Zepbound. Eli Lilly also raised its full-year 2026 revenue guidance to $85.0–$87.0 billion.
Eli Lilly Steps Up Legal Fight Over Illegal Retatrutide Sales
Eli Lilly has intensified legal action against U.S. entities accused of selling unauthorized versions of its experimental obesity drug retatrutide. The company is pursuing multiple lawsuits as part of a broader effort to curb black market distribution of the unapproved treatment. Eli Lilly is also engaging regulators and online platforms to address patient safety risks and protect its obesity drug portfolio. The company is guiding to US$85b to US$87b in 2026 revenue, with a heavy tilt toward obesity and diabetes drugs such as Mounjaro, Zepbound and future GLP-1 assets. Investors will be looking for concrete outcomes such as successful court rulings, visible reductions in unauthorized online supply, or clearer FDA and Department of Justice actions that limit compounded or gray market versions of GLP-1s and retatrutide before key Phase 3 and approval milestones.
Novo CEO Says Obesity Drug Market Won't Be Winner-Take-All
Mike Doust, chief executive of Danish pharmaceutical giant Novo Nordisk, said he does not expect the obesity drug market to become a winner-take-all battle with U.S.-based Eli Lilly. Doust noted that the market will become more segmented as new treatment options such as oral drugs emerge, describing a market where Coca-Cola, Pepsi, Fanta, Dr Pepper, and Red Bull coexist. Novo was early to launch the injectable drug Wegovy in the U.S. market, but has been losing share to Lilly's Zepbound. Analysts forecast the market will reach more than 100 billion dollars annually by 2030, and Novo's oral version of Wegovy currently holds a 90 percent share of the oral GLP-1 drug market.
Novo Nordisk CEO Reframes Obesity Race Around Pill Strategy
Novo Nordisk shares slipped about 1% Thursday morning as CEO Mike Doustdar sought to reframe the obesity drug competition as a multi-segment market rather than a winner-takes-all battle against Eli Lilly. Doustdar told Reuters that oral Wegovy already controls roughly 90% of the oral GLP-1 market, and he now believes pills could eventually take around half of the overall market, up from Novo's earlier view that oral drugs could exceed one-third of GLP-1 use by 2030. The obesity market could top $100 billion annually by 2030, and Novo is positioning a deep lineup including oral Wegovy and CagriSema, which delivered roughly 23% average weight loss in clinical testing versus more than 25% cited for Lilly's Zepbound. Novo still aims to launch CagriSema next year, while the stock trades at $45.93, about 57.74% below its GF Value estimate of $108.68.
Novo Nordisk Faces New Weight Loss Drug Competition
Novo Nordisk faces fresh competitive pressure after the UK's MHRA approved Eli Lilly's oral weight loss therapy Foundayo and Amazon Pharmacy launched a $50 per month Medicare weight loss drug program that includes Novo Nordisk and Eli Lilly medications. The UK approval adds a non-injectable option alongside Novo Nordisk's GLP-1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. The Amazon program highlights changing access and pricing dynamics in obesity care that may influence volumes and reimbursement for Novo Nordisk's flagship treatments. Novo Nordisk, a pharmaceuticals group with a DKK1.3 trillion market cap, focuses on researching, manufacturing and distributing treatments for chronic conditions such as obesity and diabetes.
Novo Nordisk GLP-1 sales flat as Lilly gains ground
Novo Nordisk reported second-quarter 2026 sales of $12.21 billion, up 3% at constant exchange rates, but its key GLP-1 brands Ozempic and Wegovy injectable were flat year over year, while Eli Lilly's Mounjaro and Zepbound surged 91% and 46% respectively. Novo Nordisk's oral GLP-1 franchise, including the Wegovy pill and Ozempic pill/Rybelsus, generated $1.31 billion in the quarter, but Lilly's newly launched oral pill Foundayo posted $98 million and could erode Novo's oral lead. Novo Nordisk has sued Lilly over advertising for Mounjaro and Zepbound, and raised its 2026 guidance to a 0-6% decline in adjusted sales and operating profit at constant exchange rates, from a prior 4-12% decline. Smaller biotechs Viking Therapeutics and Structure Therapeutics are also advancing oral GLP-1 therapies, with Viking planning phase III for VK2735 in the fourth quarter of 2026 and Structure dosing patients in its late-stage ACCOMPLISH program for aleniglipron.
CVS Health Revamps Weight Management Program, Partners with Eli Lilly
CVS Health announced a revamp of its weight management program to improve access, affordability, and support for GLP-1 medications. The company is collaborating with Eli Lilly and Company to provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app, with transparent pricing including cash-pay options expected by early fourth quarter of 2026. CVS Pharmacy offers all FDA approved GLP-1s, and MinuteClinic digital weight loss visits have been lowered to $29, the most affordable option in the market, available 24/7 with no membership or recurring monthly fee. The program combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and in-person pharmacist support in one connected experience. CVS Pharmacy also participates in the Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge program, which runs through December 31, 2027, offering eligible Medicare beneficiaries certain GLP-1 medications for $50 per month.